LAUSR

Systemic inflammatory response syndrome (SIRS) development is accompanied by mitochondrial dysfunction and excessive ROS production. Mitochondrial dysfunctions also occur in many SIRS‐related diseases and may be critical for their pathogenesis; therefore, a use of mitochondria‐targeted drugs is a promising trend in SIRS research and therapy. Here, we review recent studies concerning the application of the mitochondria‐targeted antioxidants and uncouplers of oxidative phosphorylation in animal models of SIRS and related diseases. We propose that a new class of uncouplers of oxidative phosphorylation, lipophilic cations could be a base for a new generation of drugs for SIRS treatment. J. Cell. Physiol. 232: 904–912, 2017. © 2016 Wiley Periodicals, Inc.